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During homeostasis several endogenous mechanisms exist to modulate EGFR pathway activity. 
These include 1) ligand–receptor choice and binding affinity, 2) EGFR homo- and 
heterodimerisation, 3) extracellular ligand release and receptor–ligand segregation, 4) cytoplasmic 
and cell surface antagonist abundance, 5) rate of intracellular receptor recycling, and 6) 
downstream pathway choice causing differential gene expression. MEK/ERK: MAPK 
kinase/extracellular signal-regulated kinase; PI3K: phosphatidylinositol-3-kinase; JAK/STAT: 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































Gene	 	 Reference	 Sequence	 Bases	
Cre	insert	 5	 Professor	Kim	Jensen	 GCC	TGC	ATT	ACC	GGT	CGA	TGC	AAC	
GA	
700	










































1	 94	 30	 94	 30	 94	 30	
2	 94	 30	 94	 30	 94	 30	
3	 67	 30	 62	 30	 61	 30	














Primer	 Bases	 Direction	 Sequence	
A	 353	 5’	 GAG	TCG	GGC	GTC	CAT	GTC	
	 	 3’	 CAA	AGG	CGA	TAC	TCA	CAG	GC	
B	 355	 5’	 CGG	CGC	GTT	CCA	GAC	AAG	
	 	 3’	 CAC	CCA	CAA	GTC	TCC	CAG	
C	 393	 5’	 CTG	GAG	TCG	GGC	GTC	CAT	
















































































































































































































Antigen	 Colour	 Antibody	 Reactivity	 Concentration	




CD31	 BV421	 303124,	Biolegend,	UK	 human	 1:100	
CD31	 PE-Cy7	 102417,	Biolegend,	UK	 mouse	 1:100	
CD45	 PE	 103105,	Biolegend	UK	 mouse	 1:100	
CD45	 PE	 368510,	Biolegend	UK	 human	 1:100	
CD45	 BV421	 304032,	Biolegend	UK	 human	 1:100	
CD49f	 APC	 17-0495-80,	EBioscience	 mouse/	
human	
1:100	
EpCAM	 BV711	 BD	Biosciences,	UK	 mouse	 1:100	
Isolectin	
GS-IB4	












LRIG1	 PE	 FAB7498P,	R	and	D	Systems	 human	 1:100	























































































































Antigen	 Antibody	 Species	 Concentration	 Antigen	Retrieval		
eGFP	 Abcam	ab13970	 Chicken	 1:1000	 0.2%	Triton	X	
FOXJ1	 EBioscience		14-9965-80	 Mouse	IgG1	 1:50	 Nil	
LRIG1	 R	and	D	Systems	AF3688	 Goat	 1:200	 0.2%	Triton	X/	
citrate	
Tdtomato	 Rockland	600-401-379	 Rabbit	 1:1000	 0.2%	Triton	X	
Ki67	 Abcam	ab15580	 Rabbit	 1:100	 Citrate	
Ki67	 Biolegend	151202	 Rat	IgG2b	 1:200	 Citrate	
GS-IB4	 L2895	Sigma,	488	conjugate	 	 1:75	 Citrate	
KRT5	 Abcam	ab24647	 Rabbit	 1:1000	 Citrate/	0.2%	
Triton	X	











Phospho-EGFR	 Invitrogen	36-9700	 Rabbit	 1:500	 Citrate	
SPC	 Santa	Cruz	SC-7706	 Goat	 1:50	 Citrate	
TTF1	 Novocastra	NCL-L-TTF-1	 Mouse	IgG1	 1:200	 Citrate	
CC10	 Santa	Cruz	SC-9772	 Goat	 1:400	 Citrate	
	 66	
CC10	 Santa	Cruz	SC-365992	 Mouse	IgG1	 1:400	 Citrate	
Annexin	5	 Abcam	ab14196	 Rabbit	 1	μg/ml	 Citrate	









































































































































































































































































































































































Rabbit	 Abcam	 Ab36707	 1	μg/ml	
LRIG1	
(anti	human)	
Rabbit	 Cell	Signalling	Technologies	 #12752	 1:1000	
α-tubulin	 Rabbit	 Cell	Signalling	Technologies	 #9099	 1:1000	
EGFR	 Rabbit	 Cell	Signalling	Technologies	 #4267	 1:1000	
phospho-EGFR	 Rabbit	 Cell	Signalling	Technologies	 #2234	 1:1000	
ERK	½	 Rabbit	 Cell	Signalling	Technologies	 #9102	 1:1000	
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































	 Gender	 Age	 History	 Smoking,	pack	
years	
Site	 Histology	 Experiment	











C	 F	 77	 Surveillance	 Ex	smoker	 	 Normal	
epithelium	
Cell	culture	





























































































Q	 F	 58	 CIS	surveillance	 50,	ex	smoker	
2000	
Right	main	
bronchus	
Normal	
epithelium	
Proliferation	
	 237	
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